title: An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
abstract: OBJECTIVE
  To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
  
  
  METHODS
  In this multicentre, open-label and non-comparative study, a total of 135 sexually active patients with LUTS were enrolled in Korea to receive alfuzosin 10 mg once daily for 12 weeks. International Prostate Symptom Score (IPSS) and a 25-item MSHQ exploring erection ejaculation and satisfaction with sex life were evaluated at baseline after 4 and 12 weeks of treatment.
  
  
  RESULTS
  Of 135 patients (age 58.8 years, duration of LUTS 2.6 years, mean values), 110 (81.5%) completed the study. The ejaculatory domain of the MSHQ significantly improved at the end-point in the intent-to-treat population (score difference of 2.24, p < or = 0.0001, n = 120). The domains of erection and sexual satisfaction improved at the end-point, but the score differences were not statistically significant. After the 12 weeks treatment, the total IPSS score significantly decreased from 17.9 to 12.1 (p < 0.0001), bother score decreased from 3.8 to 2.85 (p < 0.0001) and peak flow rate increased from 11.0 to 14.3 ml/s (p < 0.0001). A significant relationship between ejaculatory domains of MSHQ and IPSS was found. Four patients (2.9%) discontinued the trial for adverse event.
  
  
  CONCLUSIONS
  Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction.
authors.affiliation: Department of Urology and Institute for Medical Sciences, Chonbuk National University Medical School and Research Institute of Clinical Medicine, CTC of Medical Device of Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: M K
authors.initials: MK
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Cheon
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: M K
authors.initials: MK
authors.lastname: Chung
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: S W
authors.initials: SW
authors.lastname: Lee
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.forename: B H
authors.initials: BH
authors.lastname: Chung
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: J K
authors.initials: JK
authors.lastname: Park
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D004542:Ejaculation / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011470:Prostatic Hyperplasia / Q000150:complications*; D053448:Prostatism / Q000150:complications*; D011799:Quinazolines / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D011795:Surveys and Questionnaires
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D011799:Quinazolines; C047638:alfuzosin